JIC
LGND icon

Johnson Investment Counsel’s Ligand Pharmaceuticals LGND Stock Holding History

Johnson Investment Counsel’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,395
Closed -$349K – 642
2018
Q1 		$349K Sell
3,395
-37
-1% -$3.66K 0.01% 495
2017
Q4 		$293K Buy
3,432
+71
+2% +$6.15K 0.01% 527
2017
Q3 		$285K Hold
3,361
– – 0.01% 521
2017
Q2 		$254K Buy
+3,361
New +$235K 0.01% 544

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Johnson Investment Counsel's LGND Position: Q2 2018 in Review

Johnson Investment Counsel sold out of Ligand Pharmaceuticals (LGND) in Q2 2018, closing a stake of 3,395 shares — an estimated $349K sold.

Johnson Investment Counsel first reported a position in LGND in Q2 2017 and held it in 4 quarters. The position peaked at $349K in Q1 2018. 346 funds tracked by Wall St. Rank hold LGND as of Q2 2018.

  • Johnson Investment Counsel reported no remaining Ligand Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Johnson Investment Counsel sold 3,395 Ligand Pharmaceuticals shares in Q2 2018, an estimated $349K.
  • Johnson Investment Counsel first reported a position in Ligand Pharmaceuticals in Q2 2017 and held it in 4 quarters.
  • Johnson Investment Counsel's Ligand Pharmaceuticals position peaked at $349K in Q1 2018.
  • 346 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2018.

Based on Johnson Investment Counsel's 13F filing for Q2 2018, filed 14 Aug 2018.